Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Plasentabiologi i helse og sykdom

6. november 2026 oppdatert av: University of Oxford

Pre-eclampsia (PET) is a condition characterised by high blood pressure and damage to other organs, and is a leading cause of maternal and fetal complications such as fetal growth restriction (FGR). Gestational diabetes mellitus (GDM) involves abnormal blood sugar levels during pregnancy and can have both short and long-term impacts on the health of the mother and child. Both conditions are linked to placental dysfunction but the precise mechanisms behind these links remain unclear.

A major focus of this study is on extracellular vesicles (EVs) which are tiny, bubble-like particles released by the placenta into the mother's and baby's bloodstreams. These EVs act as messengers, carrying proteins, lipids and genetic material that can influence how cells function, even in parts of the body far from the placenta. Notably, the number and content of these EVs change in conditions like PET and GDM, suggesting they may play a role in the development of these complications.

This single-site, observational, laboratory study aims to investigate how these EVs contribute to maternal health and disease. To enable analysis across different physiological and pathological conditions pregnant participants with healthy pregnancies, pregnancies predisposed to PET and pregnancies complicated by GDM, FGR and PET will be recruited alongside healthy non-pregnant controls. Recruitment will be from the Oxford University Hospitals NHS Foundation Trust and the Nuffield Department of Women's and Reproductive Health, University of Oxford (who fund the research). Demographic and clinical data will be collected as well as blood, urine, breath, voice, placenta, umbilical cord, umbilical cord blood, amniotic fluid and/or uterine vein blood samples.

Through examining EV content and function, it is hoped a better understanding of their role in pregnancy complications will be gained, including their potential as non-invasive biomarkers for early detection and targeted treatments, improving outcomes for mothers and babies worldwide.

Studieoversikt

Status

Rekruttering

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

The study is a non-interventional, observational study focused on sample collection and laboratory-based analyses to investigate the role of placental EVs and soluble factors in maternal and fetal health. The study will focus on understanding the molecular mechanisms underlying pre-eclampsia, gestational diabetes mellitus and fetal growth restriction, with the ultimate aim of identifying biomarkers and therapeutic targets. To achieve this, the study will recruit participants with healthy, pathological and predisposed pregnancies alongside non-pregnant healthy controls.

Studietype

Observasjonsmessig

Registrering (Antatt)

1000

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Hunn

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

This study will recruit a diverse cohort of pregnant and non-pregnant participants to enable analysis of placental EVs and soluble factors across different physiological and pathological conditions.

Participants will include:

  • Pregnant women with pre-eclampsia, gestational diabetes mellitus or fetal growth restriction to allow the study of disease-specific alterations in EVs and systemic responses.
  • Pregnant women predisposed to pre-eclampsia to provide insights into risk factors and early-stage changes, aiding in biomarker discovery for prediction and prevention.
  • Pregnant women with healthy pregnancies to understand normal EV release and immune regulation.
  • Non-pregnant women to provide critical baseline data to differentiate the effects of pregnancy from underlying physiological processes.

Pregnant participants may be recruited at any gestational stage to ensure a comprehensive coverage of pregnancy progression.

Beskrivelse

Inclusion Criteria:

  • Female, aged 18 years or above

  • Willing and able to give informed consent for participation in the study

  • Able to read and understand written and spoken English to comprehend study materials and give informed consent

  • Non-pregnant women in good general health OR pregnant women who fall into one of the following:

    • Healthy pregnancy
    • Pre-eclampsia (PET) - defined by clinical diagnostic criteria, including hypertension and proteinuria
    • Gestational diabetes mellitus (GDM) - diagnosed by standard glucose tolerance tests during pregnancy
    • Fetal growth restriction (FGR) - diagnosed based on fetal weight or Doppler abnormalities
    • Predisposed to PET - high-risk factors for PET such as maternal type 1 or type 2 diabetes, autoimmune diseases or multiple pregnancies

Exclusion Criteria:

  • Non-pregnant participants with active health conditions that could confound study outcomes
  • Pregnant participants with conditions unrelated to PET, GDM or FGR that could influence EV profiles e.g. active infections or malignancies

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Observasjonsmodeller: OTHER
  • Tidsperspektiver: OTHER

Kohorter og intervensjoner

Gruppe / Kohort
Intervensjon / Behandling
Gravide kvinner diagnostisert med preeklampsi

There are no interventions for this study

Gravide kvinner diagnostisert med svangerskapsdiabetes

There are no interventions for this study

Gravide kvinner diagnostisert med fostervekstbegrensning

There are no interventions for this study

Friske gravide kvinner

There are no interventions for this study

Friske ikke-gravide kvinner

There are no interventions for this study

Gravide kvinner med disposisjon for preeklampsi

There are no interventions for this study

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Enhanced understanding of the molecular and cellular mechanisms linking placental EVs to maternal systemic inflammation in PET and GDM.
Tidsramme: Baseline and at delivery

Quantitative (number of particles/ml) and qualitative differences (protein cargo) in EV profiles

Baseline and at delivery

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Quantitative and qualitative differences in inflammatory immune cells
Tidsramme: baseline and delivery

Quantitative (cells/ml) and qualitative (protein and RNA composition/mg cell) will be measured

baseline and delivery
Sensitivity, specificity and predictive value of EVs for identifying PET, GDM and other pregnancy complications
Tidsramme: Baseline and delivery

Standard statistical analysis of EV parameters against clinical endpoints to derive sensitivity, specificity and PPV/NPV in these disease conditions

Baseline and delivery

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

16. desember 2025

Primær fullføring (Antatt)

31. mai 2030

Studiet fullført (Antatt)

31. mai 2030

Datoer for studieregistrering

Først innsendt

10. desember 2025

Først innsendt som oppfylte QC-kriteriene

9. mars 2026

Først lagt ut (Faktiske)

13. mars 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

9. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

6. november 2026

Sist bekreftet

1. desember 2025

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • 18939

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

UBESLUTTE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .